Comparative Pharmacology
Head-to-head clinical analysis: PROMETHAZINE DM versus TAVIST 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHAZINE DM versus TAVIST 1.
PROMETHAZINE DM vs TAVIST-1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic via blockade of dopamine D2 receptors in the chemoreceptor trigger zone, and sedative via central anticholinergic effects. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist, suppressing cough by central action on the cough center.
TAVIST-1 (clemastine fumarate) is a first-generation antihistamine that acts as a competitive antagonist at histamine H1 receptors, thereby preventing histamine-mediated effects such as vasodilation, increased capillary permeability, and bronchoconstriction. It also exhibits anticholinergic and sedative properties.
2 teaspoonfuls (10 mL) orally every 4-6 hours, not to exceed 8 teaspoonfuls (40 mL) per 24 hours.
1.34 mg orally twice daily; maximum 8.04 mg/day.
None Documented
None Documented
16-19 hours (terminal); note: effect may last longer due to active metabolites and tissue binding
Terminal half-life 12–15 hours; clinical dosing interval every 12 hours.
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Primarily renal: ~60% unchanged; biliary/fecal: ~30% as metabolites; minor via feces.
Category A/B
Category C
Antihistamine / Antiemetic
Antihistamine